These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 20031733)

  • 21. Long-term clinical outcomes after percutaneous coronary intervention for ostial/mid-shaft lesions versus distal bifurcation lesions in unprotected left main coronary artery: the DELTA Registry (drug-eluting stent for left main coronary artery disease): a multicenter registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment.
    Naganuma T; Chieffo A; Meliga E; Capodanno D; Park SJ; Onuma Y; Valgimigli M; Jegere S; Makkar RR; Palacios IF; Costopoulos C; Kim YH; Buszman PP; Chakravarty T; Sheiban I; Mehran R; Naber C; Margey R; Agnihotri A; Marra S; Capranzano P; Leon MB; Moses JW; Fajadet J; Lefevre T; Morice MC; Erglis A; Tamburino C; Alfieri O; Serruys PW; Colombo A
    JACC Cardiovasc Interv; 2013 Dec; 6(12):1242-9. PubMed ID: 24355114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-eluting stents and glycoprotein IIb/IIIa inhibitors in vessels at low anatomic risk: a retrospective analysis of previously published data from the Basel Stent Kosten Effektivitäts Trial.
    Jeger RV; Brunner-La Rocca HP; Hunziker PR; Tsakiris DA; Kaiser CA; Pfisterer ME;
    Clin Ther; 2009 Dec; 31(12):2886-93. PubMed ID: 20110027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative analysis of major clinical outcomes using drug-eluting stents versus bare metal stents in diabetic versus nondiabetic patients.
    Minha S; Bental T; Assali A; Vaknin-Assa H; Lev EI; Rechavia E; Battler A; Kornowski R
    Catheter Cardiovasc Interv; 2011 Nov; 78(5):710-7. PubMed ID: 21805561
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multivessel drug-eluting stenting and impact of diabetes mellitus--a report from the EVENT registry.
    Novack V; Tsyvine D; Cohen DJ; Pencina M; Dubin J; Dehghani H; Kleiman NS; Cutlip DE
    Catheter Cardiovasc Interv; 2009 Jun; 73(7):874-80. PubMed ID: 19180665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term benefits and risks of drug-eluting compared to bare-metal stents in patients with versus without chronic kidney disease.
    Wanitschek M; Pfisterer M; Hvelplund A; De Servi S; Bertel O; Jeger R; Rickenbacher P; Iversen A; Jensen JS; Galatius S; Kaiser C; Alber H;
    Int J Cardiol; 2013 Oct; 168(3):2381-8. PubMed ID: 23453439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term clinical outcomes following drug-eluting stent implantation for unprotected distal trifurcation left main disease: the Milan-New Tokyo (MITO) registry.
    Ielasi A; Takagi K; Latib A; Basavarajaiah S; Figini F; Carlino M; Montorfano M; Chieffo A; Nakamura S; Colombo A
    Catheter Cardiovasc Interv; 2014 Mar; 83(4):530-8. PubMed ID: 23983065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of the SYNTAX score for predicting clinical outcome after percutaneous coronary intervention of unprotected left main coronary artery disease.
    Capodanno D; Di Salvo ME; Cincotta G; Miano M; Tamburino C; Tamburino C
    Circ Cardiovasc Interv; 2009 Aug; 2(4):302-8. PubMed ID: 20031732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of multivessel stenting on top of percutaneous revascularization for unprotected left main disease in the drug-eluting stent era: insights from the Turin registry.
    Sheiban I; Sillano D; Biondi-Zoccai G; Moretti C; Garrone P; Lombardi P; Sciuto F; Omedè P; Iacovino C; Spina CL; Trevi GP
    J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):461-8. PubMed ID: 19395977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic values of C-reactive protein levels on clinical outcome after implantation of sirolimus-eluting stents in patients on hemodialysis.
    Ishii H; Toriyama T; Aoyama T; Takahashi H; Amano T; Hayashi M; Tanaka M; Kawamura Y; Yasuda Y; Yuzawa Y; Maruyama S; Matsuo S; Matsubara T; Murohara T
    Circ Cardiovasc Interv; 2009 Dec; 2(6):513-8. PubMed ID: 20031768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and effectiveness of drug-eluting stents versus bare-metal stents in elderly patients with small coronary vessel disease.
    Puymirat E; Mangiacapra F; Peace A; Ntarladimas Y; Conte M; Bartunek J; Vanderheyden M; Wijns W; de Bruyne B; Barbato E
    Arch Cardiovasc Dis; 2013 Nov; 106(11):554-61. PubMed ID: 24231052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcomes of treatment by percutaneous coronary intervention versus coronary artery bypass graft surgery in patients with chronic kidney disease undergoing index revascularization in Ontario.
    Chan W; Ivanov J; Ko D; Fremes S; Rao V; Jolly S; Cantor WJ; Lavi S; Overgaard CB; Ruel M; Tu JV; Džavík V
    Circ Cardiovasc Interv; 2015 Jan; 8(1):. PubMed ID: 25582144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of chronic kidney disease on the prognosis of patients undergoing percutaneous coronary interventions using drug-eluting stents.
    Kaya E; Cuneo A; Hochadel M; Jünger C; Stepper W; Bramlage P; Kuck KH; Nienaber CA; Senges J; Eckardt L; Tebbe U; Reinecke H
    Clin Res Cardiol; 2011 Dec; 100(12):1103-9. PubMed ID: 21912915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deployment of drug-eluting stents for isolated proximal lad disease is associated with lower major adverse cardiac events and no increase in stent thrombosis when compared with bare metal stents: a 5-year observational cohort study.
    Jones DA; Rathod KS; Gallagher S; Weerackody R; Knight CJ; Rothman MT; Mathur A; Jain AK; Timmis AD; Wragg A
    Catheter Cardiovasc Interv; 2013 May; 81(6):E237-44. PubMed ID: 22707383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic Kidney Disease in the Second-Generation Drug-Eluting Stent Era: Pooled Analysis of the Korean Multicenter Drug-Eluting Stent Registry.
    Lee JM; Kang J; Lee E; Hwang D; Rhee TM; Park J; Kim HL; Lee SE; Han JK; Yang HM; Park KW; Na SH; Kang HJ; Koo BK; Kim HS
    JACC Cardiovasc Interv; 2016 Oct; 9(20):2097-2109. PubMed ID: 27692820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes in patients with renal impairment undergoing percutaneous coronary intervention and implantation of the Endeavor zotarolimus-eluting stent: 1- and 2-year data from the E-Five Registry.
    Rothman MT; Jain AK;
    Catheter Cardiovasc Interv; 2012 Nov; 80(6):885-92. PubMed ID: 22517785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial.
    Garg S; Serruys PW; Silber S; Wykrzykowska J; van Geuns RJ; Richardt G; Buszman PE; Kelbæk H; van Boven AJ; Hofma SH; Linke A; Klauss V; Wijns W; Macaya C; Garot P; DiMario C; Manoharan G; Kornowski R; Ischinger T; Bartorelli A; Van Remortel E; Ronden J; Windecker S
    JACC Cardiovasc Interv; 2011 Apr; 4(4):432-41. PubMed ID: 21511223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic kidney disease and the risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents.
    Miao Y; Yu-Jie Z; Zhi-Jian W; Dong-Mei S; Yu-Yang L; Ying-Xin Z; Fei G; Shi-Wei Y; De-An J
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):361-7. PubMed ID: 22419375
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients.
    Halkin A; Selzer F; Marroquin O; Laskey W; Detre K; Cohen H
    J Invasive Cardiol; 2006 Dec; 18(12):577-83. PubMed ID: 17197706
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcome of provisional side-branch T-stenting for the treatment of unprotected distal left main coronary artery disease.
    De Luca L; Altamura L; Corvo P; De Persio G; Ghini AS; Petrolini A; Aurigemma C; Tomai F
    Catheter Cardiovasc Interv; 2011 May; 77(6):765-72. PubMed ID: 21413124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.